modafinil has been researched along with Neoplasms in 31 studies
Modafinil: A benzhydryl acetamide compound, central nervous system stimulant, and CYP3A4 inducing agent that is used in the treatment of NARCOLEPSY and SLEEP WAKE DISORDERS.
modafinil : A racemate comprising equimolar amounts of armodafinil and (S)-modafinil. A central nervous system stimulant, it is used for the treatment of sleeping disorders such as narcolepsy, obstructive sleep apnoea, and shift-work sleep disorder. The optical enantiomers of modafinil have similar pharmacological actions in animals.
2-[(diphenylmethyl)sulfinyl]acetamide : A sulfoxide that is dimethylsulfoxide in which two hydrogens attached to one of the methyl groups are replaced by phenyl groups, while one hydrogen attached to the other methyl group is replaced by a carbamoyl (aminocarbonyl) group.
Neoplasms: New abnormal growth of tissue. Malignant neoplasms show a greater degree of anaplasia and have the properties of invasion and metastasis, compared to benign neoplasms.
| Excerpt | Relevance | Reference |
|---|---|---|
| "The aim of this study was to compare the efficacy and safety of modafinil and dexamethasone in the management of cancer-related fatigue and their effects on quality of life (QoL)." | 9.41 | Efficacy and safety of modafinil versus dexamethasone in cancer-related fatigue: a prospective randomized controlled study. ( Banerjee, S; Bhattacharya, B; Biswas, S; Deb, U; Mukhopadhyay, S, 2021) |
| "CBT-I with and without armodafinil resulted in a clinically and statistically significant reduction of subjective daytime fatigue in cancer survivors with chronic insomnia." | 9.22 | Cognitive behavioral therapy for insomnia, but not armodafinil, improves fatigue in cancer survivors with insomnia: a randomized placebo-controlled trial. ( Garland, SN; Heckler, CE; Hoefler, J; Kamen, C; Morrow, GR; Peoples, AR; Perlis, ML; Roscoe, JA; Shayne, M, 2016) |
| "The aim of this study was to examine the effect of modafinil on depression via a secondary data analysis of a randomized clinical trial of modafinil for fatigue in cancer patients." | 9.22 | Modafinil Moderates the Relationship Between Cancer-Related Fatigue and Depression in 541 Patients Receiving Chemotherapy. ( Conley, CC; Dakhil, S; Gross, H; Heckler, CE; Janelsins, MC; Kamen, CS; Morrow, GR; Mustian, KM; Palesh, OG; Peppone, LJ; Scalzo, AJ, 2016) |
| "This study involves the analysis of a secondary outcome of a trial examining whether cognitive behavior therapy for insomnia (CBT-I), a wake-promoting medication (armodafinil), or both results in greater improvement in prospectively assessed sleep continuity and daytime sleepiness than a placebo-alone group among a heterogeneous group of cancer survivors." | 9.22 | Effects of armodafinil and cognitive behavior therapy for insomnia on sleep continuity and daytime sleepiness in cancer survivors. ( Barilla, H; Findley, JC; Garland, SN; Gehrman, P; Heckler, CE; Kamen, C; Morrow, GR; Peoples, AR; Perlis, ML; Roscoe, JA, 2016) |
| "Modafinil may be useful in controlling cancer-related fatigue in patients who present with severe fatigue but is not useful in patients with mild or moderate fatigue." | 9.14 | A phase 3 randomized, placebo-controlled, double-blind, clinical trial of the effect of modafinil on cancer-related fatigue among 631 patients receiving chemotherapy: a University of Rochester Cancer Center Community Clinical Oncology Program Research bas ( Esparaz, BT; Heckler, C; Hemstad, A; Hopkins, JO; Janelsins, M; Jean-Pierre, P; Mohile, S; Morrow, GR; Peppone, L; Roscoe, JA, 2010) |
| "To review the efficacy and safety of modafinil in the treatment of cancer-related fatigue (CRF)." | 8.85 | Efficacy and safety of modafinil in the treatment of cancer-related fatigue. ( Bird, HM; Cooper, MR; Steinberg, M, 2009) |
| "the authors conducted an open-label investigation examining the effects of modafinil in reducing fatigue in patients with cancer, undergoing cancer treatment, and receiving opioid therapy." | 7.76 | [Modafinil for the treatment of cancer-related fatigue : an intervention study]. ( Junker, U; Kühn, KU; Nadstawek, J; Vater, S; Wartenberg, HC; Wirz, S, 2010) |
| "The aim of this study was to compare the efficacy and safety of modafinil and dexamethasone in the management of cancer-related fatigue and their effects on quality of life (QoL)." | 5.41 | Efficacy and safety of modafinil versus dexamethasone in cancer-related fatigue: a prospective randomized controlled study. ( Banerjee, S; Bhattacharya, B; Biswas, S; Deb, U; Mukhopadhyay, S, 2021) |
| "CBT-I with and without armodafinil resulted in a clinically and statistically significant reduction of subjective daytime fatigue in cancer survivors with chronic insomnia." | 5.22 | Cognitive behavioral therapy for insomnia, but not armodafinil, improves fatigue in cancer survivors with insomnia: a randomized placebo-controlled trial. ( Garland, SN; Heckler, CE; Hoefler, J; Kamen, C; Morrow, GR; Peoples, AR; Perlis, ML; Roscoe, JA; Shayne, M, 2016) |
| "The aim of this study was to examine the effect of modafinil on depression via a secondary data analysis of a randomized clinical trial of modafinil for fatigue in cancer patients." | 5.22 | Modafinil Moderates the Relationship Between Cancer-Related Fatigue and Depression in 541 Patients Receiving Chemotherapy. ( Conley, CC; Dakhil, S; Gross, H; Heckler, CE; Janelsins, MC; Kamen, CS; Morrow, GR; Mustian, KM; Palesh, OG; Peppone, LJ; Scalzo, AJ, 2016) |
| "This study involves the analysis of a secondary outcome of a trial examining whether cognitive behavior therapy for insomnia (CBT-I), a wake-promoting medication (armodafinil), or both results in greater improvement in prospectively assessed sleep continuity and daytime sleepiness than a placebo-alone group among a heterogeneous group of cancer survivors." | 5.22 | Effects of armodafinil and cognitive behavior therapy for insomnia on sleep continuity and daytime sleepiness in cancer survivors. ( Barilla, H; Findley, JC; Garland, SN; Gehrman, P; Heckler, CE; Kamen, C; Morrow, GR; Peoples, AR; Perlis, ML; Roscoe, JA, 2016) |
| "In this pilot study modafinil was well-tolerated and effective for fatigue in patients with cancer." | 5.14 | A pilot study evaluating the safety and efficacy of modafinal for cancer-related fatigue. ( Baum, L; Blackhall, L; Farace, E; Petroni, G; Shu, J, 2009) |
| "Modafinil may be useful in controlling cancer-related fatigue in patients who present with severe fatigue but is not useful in patients with mild or moderate fatigue." | 5.14 | A phase 3 randomized, placebo-controlled, double-blind, clinical trial of the effect of modafinil on cancer-related fatigue among 631 patients receiving chemotherapy: a University of Rochester Cancer Center Community Clinical Oncology Program Research bas ( Esparaz, BT; Heckler, C; Hemstad, A; Hopkins, JO; Janelsins, M; Jean-Pierre, P; Mohile, S; Morrow, GR; Peppone, L; Roscoe, JA, 2010) |
| " We included studies investigating pemoline and modafinil in participants with multiple sclerosis (MS)-associated fatigue and methylphenidate in patients suffering from advanced cancer and fatigue in meta-analysis." | 4.91 | Pharmacological treatments for fatigue associated with palliative care. ( Cuhls, H; Minton, O; Mücke, M; Peuckmann-Post, V; Radbruch, L; Stone, P, 2015) |
| "For the relief of chemotherapy symptoms in cancer patients, methylphenidate and modafinil were no more effective than placebo, although findings suggest that these psychostimulants may provide some benefit in patients who are suffering more severe asthenia or who are at advanced stages of the cancer." | 4.87 | The use of psychostimulants in cancer patients. ( Centeno, C; Portela, MA; Rubiales, AS, 2011) |
| " Studies investigating amantadine, pemoline, and modafinil in participants with Multiple Sclerosis (MS)-associated fatigue and methylphenidate in patients suffering from advanced cancer and fatigue could be used for meta-analysis." | 4.86 | Pharmacological treatments for fatigue associated with palliative care. ( Elsner, F; Krumm, N; Peuckmann, V; Radbruch, L; Trottenberg, P, 2010) |
| "To review the efficacy and safety of modafinil in the treatment of cancer-related fatigue (CRF)." | 4.85 | Efficacy and safety of modafinil in the treatment of cancer-related fatigue. ( Bird, HM; Cooper, MR; Steinberg, M, 2009) |
| "the authors conducted an open-label investigation examining the effects of modafinil in reducing fatigue in patients with cancer, undergoing cancer treatment, and receiving opioid therapy." | 3.76 | [Modafinil for the treatment of cancer-related fatigue : an intervention study]. ( Junker, U; Kühn, KU; Nadstawek, J; Vater, S; Wartenberg, HC; Wirz, S, 2010) |
| "Methylphenidate and modafinil were equivalent to one another." | 3.01 | Cancer-related fatigue-pharmacological interventions: systematic review and network meta-analysis. ( Boldt, G; Bruera, E; Chiu, L; Chow, R; Lock, M; Prsic, E; Sanatani, M, 2023) |
| "We included participants with advanced cancer who were suffering from CRF." | 3.01 | Corticosteroids for the management of cancer-related fatigue in adults with advanced cancer. ( Foster, K; Good, P; Hardy, JR; Haywood, A; Khan, S; Rickett, K; Sandford, A, 2023) |
| "In cancer survivors with insomnia, CBT-I resulted in clinically significant improvement in QOL via improvement in insomnia." | 2.84 | Effects of cognitive behavioral therapy for insomnia and armodafinil on quality of life in cancer survivors: a randomized placebo-controlled trial. ( Garland, SN; Heckler, CE; Janelsins, MC; Kamen, CS; Morrow, GR; Mustian, KM; Peoples, AR; Peppone, LJ; Perlis, ML; Roscoe, JA; Ryan, JL; Savard, J, 2017) |
| "Insomnia was assessed by the Insomnia Severity Index and sleep quality by the Pittsburgh Sleep Quality Inventory." | 2.80 | Randomized placebo-controlled trial of cognitive behavioral therapy and armodafinil for insomnia after cancer treatment. ( Daniels, NP; Garland, SN; Heckler, CE; Morrow, GR; Peoples, AR; Perlis, ML; Roscoe, JA; Savard, J; Shayne, M, 2015) |
| "MLN8054 dosing for up to 14 days of a 28-day cycle was feasible." | 2.76 | Phase 1 study of MLN8054, a selective inhibitor of Aurora A kinase in patients with advanced solid tumors. ( Burris, H; Cohen, RB; Danaee, H; Dees, EC; Ecsedy, J; Eton, O; Fingert, H; Galvin, K; Infante, JR; Jones, S; Lee, Y; Liu, H; Manfredi, M; O'Neil, BH; Stringer, B; von Mehren, M, 2011) |
| "Fatigue is a common symptom experienced by people with cancer and other long-term, non-malignant conditions." | 2.61 | The holistic management of fatigue within palliative care. ( Dean, A, 2019) |
| "Pharmacotherapeutic approaches for cancer therapy-induced cognitive symptoms include CNS stimulants (eg, methylphenidate and modafinil), medications used in patients with memory impairment (eg, donepezil, memantine, and ginkgo biloba), and bone marrow supporting agents (eg, erythropoietin)." | 2.61 | Pharmacologic management of cognitive impairment induced by cancer therapy. ( Dietrich, J; Karschnia, P; Parsons, MW, 2019) |
| "Survivors of childhood cancer frequently experience cancer-related cognitive dysfunction, commonly months to years after treatment for pediatric brain tumors, acute lymphoblastic leukemia (ALL), or tumors involving the head and neck." | 2.50 | Developing interventions for cancer-related cognitive dysfunction in childhood cancer survivors. ( Castellino, SM; Lange, BJ; Ullrich, NJ; Whelen, MJ, 2014) |
| "Methylphenidate has been studied most and is effective and well tolerated despite common side effects." | 2.44 | Pharmacologic treatment options for cancer-related fatigue: current state of clinical research. ( Alici, Y; Breitbart, W, 2008) |
| "All patients with cancer should be evaluated for fatigue, and treatment options should be considered for those who are experiencing excessive levels of fatigue." | 2.43 | Management of cancer-related fatigue. ( Hickok, JT; Morrow, GR; Mustian, K; Roscoe, JA; Shelke, AR, 2005) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 8 (25.81) | 29.6817 |
| 2010's | 20 (64.52) | 24.3611 |
| 2020's | 3 (9.68) | 2.80 |
| Authors | Studies |
|---|---|
| Lin, R | 1 |
| Elf, S | 1 |
| Shan, C | 1 |
| Kang, HB | 1 |
| Ji, Q | 1 |
| Zhou, L | 1 |
| Hitosugi, T | 1 |
| Zhang, L | 1 |
| Zhang, S | 1 |
| Seo, JH | 1 |
| Xie, J | 1 |
| Tucker, M | 1 |
| Gu, TL | 1 |
| Sudderth, J | 1 |
| Jiang, L | 1 |
| Mitsche, M | 1 |
| DeBerardinis, RJ | 1 |
| Wu, S | 1 |
| Li, Y | 1 |
| Mao, H | 1 |
| Chen, PR | 1 |
| Wang, D | 1 |
| Chen, GZ | 1 |
| Hurwitz, SJ | 1 |
| Lonial, S | 1 |
| Arellano, ML | 1 |
| Khoury, HJ | 1 |
| Khuri, FR | 1 |
| Lee, BH | 1 |
| Lei, Q | 1 |
| Brat, DJ | 1 |
| Ye, K | 1 |
| Boggon, TJ | 1 |
| He, C | 1 |
| Kang, S | 1 |
| Fan, J | 1 |
| Chen, J | 1 |
| Chow, R | 1 |
| Bruera, E | 1 |
| Sanatani, M | 1 |
| Chiu, L | 1 |
| Prsic, E | 1 |
| Boldt, G | 1 |
| Lock, M | 1 |
| Sandford, A | 1 |
| Haywood, A | 1 |
| Rickett, K | 1 |
| Good, P | 1 |
| Khan, S | 1 |
| Foster, K | 1 |
| Hardy, JR | 1 |
| Dean, A | 1 |
| Deb, U | 1 |
| Mukhopadhyay, S | 1 |
| Bhattacharya, B | 1 |
| Banerjee, S | 1 |
| Biswas, S | 1 |
| Karschnia, P | 1 |
| Parsons, MW | 1 |
| Dietrich, J | 1 |
| Miladi, N | 1 |
| Dossa, R | 1 |
| Dogba, MJ | 1 |
| Cléophat-Jolicoeur, MIF | 1 |
| Gagnon, B | 1 |
| Barsevick, AM | 1 |
| Irwin, MR | 1 |
| Hinds, P | 1 |
| Miller, A | 1 |
| Berger, A | 1 |
| Jacobsen, P | 1 |
| Ancoli-Israel, S | 1 |
| Reeve, BB | 1 |
| Mustian, K | 2 |
| O'Mara, A | 1 |
| Lai, JS | 1 |
| Fisch, M | 1 |
| Cella, D | 1 |
| Borghgraef, C | 1 |
| Libert, Y | 1 |
| Etienne, AM | 1 |
| Delvaux, N | 1 |
| Reynaert, C | 1 |
| Razavi, D | 1 |
| Castellino, SM | 1 |
| Ullrich, NJ | 1 |
| Whelen, MJ | 1 |
| Lange, BJ | 1 |
| Roscoe, JA | 6 |
| Garland, SN | 4 |
| Heckler, CE | 5 |
| Perlis, ML | 4 |
| Peoples, AR | 4 |
| Shayne, M | 2 |
| Savard, J | 2 |
| Daniels, NP | 1 |
| Morrow, GR | 7 |
| Mücke, M | 1 |
| Cuhls, H | 1 |
| Peuckmann-Post, V | 1 |
| Minton, O | 1 |
| Stone, P | 1 |
| Radbruch, L | 2 |
| Qu, D | 1 |
| Zhang, Z | 1 |
| Yu, X | 1 |
| Zhao, J | 1 |
| Qiu, F | 1 |
| Huang, J | 1 |
| Kamen, C | 2 |
| Hoefler, J | 1 |
| Conley, CC | 1 |
| Kamen, CS | 2 |
| Janelsins, MC | 2 |
| Peppone, LJ | 3 |
| Scalzo, AJ | 1 |
| Gross, H | 1 |
| Dakhil, S | 1 |
| Mustian, KM | 3 |
| Palesh, OG | 2 |
| Barilla, H | 1 |
| Gehrman, P | 1 |
| Findley, JC | 1 |
| Ryan, JL | 1 |
| Alfano, CM | 1 |
| Heckler, C | 2 |
| Kleckner, AS | 1 |
| Kleckner, IR | 1 |
| Leach, CR | 1 |
| Mohr, D | 1 |
| Piper, BF | 1 |
| Scarpato, J | 1 |
| Smith, T | 1 |
| Sprod, LK | 1 |
| Miller, SM | 1 |
| Hampton, T | 1 |
| McNeil, C | 1 |
| Breitbart, W | 1 |
| Alici, Y | 1 |
| Cooper, MR | 1 |
| Bird, HM | 1 |
| Steinberg, M | 1 |
| Blackhall, L | 1 |
| Petroni, G | 1 |
| Shu, J | 1 |
| Baum, L | 1 |
| Farace, E | 1 |
| Lundorff, LE | 1 |
| Jønsson, BH | 1 |
| Sjøgren, P | 1 |
| Jean-Pierre, P | 1 |
| Mohile, S | 1 |
| Janelsins, M | 1 |
| Peppone, L | 1 |
| Hemstad, A | 1 |
| Esparaz, BT | 1 |
| Hopkins, JO | 1 |
| Dees, EC | 1 |
| Infante, JR | 1 |
| Cohen, RB | 1 |
| O'Neil, BH | 1 |
| Jones, S | 1 |
| von Mehren, M | 1 |
| Danaee, H | 1 |
| Lee, Y | 1 |
| Ecsedy, J | 1 |
| Manfredi, M | 1 |
| Galvin, K | 1 |
| Stringer, B | 1 |
| Liu, H | 1 |
| Eton, O | 1 |
| Fingert, H | 1 |
| Burris, H | 1 |
| Wirz, S | 1 |
| Nadstawek, J | 1 |
| Kühn, KU | 1 |
| Vater, S | 1 |
| Junker, U | 1 |
| Wartenberg, HC | 1 |
| Peuckmann, V | 1 |
| Elsner, F | 1 |
| Krumm, N | 1 |
| Trottenberg, P | 1 |
| Portela, MA | 1 |
| Rubiales, AS | 1 |
| Centeno, C | 1 |
| Shelke, AR | 1 |
| Hickok, JT | 1 |
| Spathis, A | 1 |
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| Feasibility Study of Adjunctive Bright Light Therapy (BLT) for Amelioration of Fatigue in Chinese Cancer Patients Admitted to a Palliative Care Unit[NCT04525924] | 42 participants (Anticipated) | Interventional | 2020-08-01 | Recruiting | |||
| Feasibility Study of a Hypnosis Intervention and a Cognitive Behavioral Therapy Intervention to Reduce Fatigue in Patients Undergoing Chemotherapy for Metastatic Colorectal Cancer[NCT04999306] | 60 participants (Anticipated) | Interventional | 2023-05-17 | Recruiting | |||
| Effect of Resistance Training Variable Manipulation (Intensity and Volume) on Body Composition, Fatigability and Functional Capacity in Postmenopausal Breast Cancer Survivors.[NCT03644329] | 80 participants (Anticipated) | Interventional | 2018-05-13 | Recruiting | |||
| MentalPlus® for Assessment and Rehabilitation of Cognitive Functions After Remission of Symptoms of COVID-19[NCT04632719] | 200 participants (Anticipated) | Interventional | 2020-11-08 | Recruiting | |||
| Cognitive Behavioral Therapy +/- Armodafinil for Insomnia and Fatigue Following Chemotherapy[NCT01091974] | Phase 2 | 138 participants (Actual) | Interventional | 2008-02-29 | Completed | ||
| Clinical Study on Wide Spectrum Micronutrients Supplementation in Patients With Cancer Related Fatigue During Adjuvant Chemotherapy[NCT06137833] | 92 participants (Anticipated) | Interventional | 2023-11-27 | Not yet recruiting | |||
| Randomized Controlled Study to Evaluate the Effects of Modafinil in Cancer Related Fatigue in Patients Undergoing Radiation Therapy[NCT01440621] | Phase 3 | 217 participants (Actual) | Interventional | 2010-08-31 | Completed | ||
| Phase III Randomized, Placebo-Controlled, Double-Blind Trial Of The Effect Of Modafinil On Fatigue In Cancer Patients Receiving Chemotherapy[NCT00042848] | Phase 3 | 837 participants (Anticipated) | Interventional | 2002-08-31 | Completed | ||
| A Phase I/II Study of Alisertib in Combination With Abiraterone and Prednisone for Patients With Castration-Resistant Prostate Cancer After Progression on Abiraterone[NCT01848067] | Phase 1/Phase 2 | 9 participants (Actual) | Interventional | 2013-08-14 | Completed | ||
| Randomized Controlled Trial of Exercise to Reduce Cancer Related Fatigue in Women Undergoing Radiation Treatment for Breast Cancer[NCT02846389] | 24 participants (Actual) | Interventional | 2016-06-21 | Active, not recruiting | |||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||
The Insomnia Severity Index (ISI) is a commonly used, 7-item psychometrically validated measure used to rate insomnia with 0-7 = absence of insomnia, 8-14 = subthreshold insomnia symptoms, 15-21 = moderate insomnia, and 22-28 = severe insomnia. (NCT01091974)
Timeframe: ANCOVA was employed with multiple imputation on the post-intervention score (average of the two post-intervention weeks), controlling for the score at the time of consent (pre).
| Intervention | units on a scale (Mean) |
|---|---|
| Arm 1 - (CBT-I) + Placebo | -4.93 |
| 2 - CBT-I + Armodafinil | -6.36 |
| 3- Placebo Only | 1.04 |
| 4 - Armodafinil Only | -1.43 |
"The revised Brief Fatigue Inventory (BFI) is a 9-item, patient-report instrument with established reliability and validity. The BFI allows for the rapid assessment of fatigue level in cancer patients and identifies those patients with severe fatigue. Three items ask patients to rate their fatigue now, and fatigue at its worst and usual for the last 24 hours. The 11-point scales are bounded by 0 = no fatigue and 10 = fatigue as bad as you can imagine. Using the same type of scales, the remaining questions ask patients to rate how their fatigue interferes with several functional domains, including general activity, walking, mood, work, and relations with others. These scales are bounded by 0 = does not interfere and 10 = interferes completely. A global fatigue score (ranging from 0-10) can be obtained by averaging all the items on the BFI." (NCT01091974)
Timeframe: ANCOVA was employed with multiple imputation on the post-intervention score (average of the two post-intervention weeks), controlling for the score at the time of consent (pre).
| Intervention | units on a scale (Mean) |
|---|---|
| Arm 1 - (CBT-I) + Placebo | 2.041 |
| 2 - CBT-I + Armodafinil | 1.209 |
| 3- Placebo Only | 2.971 |
| 4 - Armodafinil Only | 3.167 |
Compared between the two patient subsets using the nonparametric Mann-Whitney test. A comparison of CTC counts between baseline and at progression for those who have progressed will be carried out using either a paired t test or the nonparameteric Wilcoxon matched pairs test. (NCT01848067)
Timeframe: Baseline up to 3 months
| Intervention | Participants (Count of Participants) |
|---|---|
| Treatment (Alisertib, Abiraterone Acetate, Prednisone) | 3 |
Summarized with descriptive statistics. (NCT01848067)
Timeframe: Up to 21 days
| Intervention | Participants (Count of Participants) |
|---|---|
| Treatment (Alisertib, Abiraterone Acetate, Prednisone) | 2 |
16 reviews available for modafinil and Neoplasms
| Article | Year |
|---|---|
6-Phosphogluconate dehydrogenase links oxidative PPP, lipogenesis and tumour growth by inhibiting LKB1-AMPK signalling.
Topics: AMP-Activated Protein Kinase Kinases; AMP-Activated Protein Kinases; Humans; Lipogenesis; Neoplasms; | 2015 |
Cancer-related fatigue-pharmacological interventions: systematic review and network meta-analysis.
Topics: Central Nervous System Stimulants; Fatigue; Humans; Methylphenidate; Modafinil; Neoplasms; Network M | 2023 |
Corticosteroids for the management of cancer-related fatigue in adults with advanced cancer.
Topics: Adolescent; Adrenal Cortex Hormones; Adult; Dexamethasone; Fatigue; Humans; Modafinil; Neoplasms; Qu | 2023 |
The holistic management of fatigue within palliative care.
Topics: Central Nervous System Stimulants; Chronic Disease; Cognitive Behavioral Therapy; Complementary Ther | 2019 |
Pharmacologic management of cognitive impairment induced by cancer therapy.
Topics: Antineoplastic Agents; Central Nervous System Stimulants; Cholinesterase Inhibitors; Cognitive Dysfu | 2019 |
Psychostimulants for cancer-related cognitive impairment in adult cancer survivors: a systematic review and meta-analysis.
Topics: Adult; Cancer Survivors; Central Nervous System Stimulants; Cognition; Cognitive Dysfunction; Humans | 2019 |
[Treatment of cognitive impairments in oncology: a review of longitudinal controlled studies].
Topics: Adult; Benzhydryl Compounds; Case-Control Studies; Central Nervous System Stimulants; Cognition; Cog | 2014 |
Developing interventions for cancer-related cognitive dysfunction in childhood cancer survivors.
Topics: Adolescent; Adult; Age Factors; Antimetabolites, Antineoplastic; Attention; Benzhydryl Compounds; Br | 2014 |
Pharmacological treatments for fatigue associated with palliative care.
Topics: Adult; Amantadine; Benzhydryl Compounds; Carnitine; Central Nervous System Stimulants; Chronic Disea | 2015 |
Psychotropic drugs for the management of cancer-related fatigue: a systematic review and meta-analysis.
Topics: Benzhydryl Compounds; Fatigue; Humans; Methylphenidate; Modafinil; Neoplasms; Psychotropic Drugs | 2016 |
Comparison of Pharmaceutical, Psychological, and Exercise Treatments for Cancer-Related Fatigue: A Meta-analysis.
Topics: Benzhydryl Compounds; Central Nervous System Stimulants; Cognitive Behavioral Therapy; Dexmethylphen | 2017 |
Comparison of Pharmaceutical, Psychological, and Exercise Treatments for Cancer-Related Fatigue: A Meta-analysis.
Topics: Benzhydryl Compounds; Central Nervous System Stimulants; Cognitive Behavioral Therapy; Dexmethylphen | 2017 |
Comparison of Pharmaceutical, Psychological, and Exercise Treatments for Cancer-Related Fatigue: A Meta-analysis.
Topics: Benzhydryl Compounds; Central Nervous System Stimulants; Cognitive Behavioral Therapy; Dexmethylphen | 2017 |
Comparison of Pharmaceutical, Psychological, and Exercise Treatments for Cancer-Related Fatigue: A Meta-analysis.
Topics: Benzhydryl Compounds; Central Nervous System Stimulants; Cognitive Behavioral Therapy; Dexmethylphen | 2017 |
Pharmacologic treatment options for cancer-related fatigue: current state of clinical research.
Topics: Antidepressive Agents; Benzhydryl Compounds; Central Nervous System Stimulants; Cholinesterase Inhib | 2008 |
Efficacy and safety of modafinil in the treatment of cancer-related fatigue.
Topics: Animals; Benzhydryl Compounds; Fatigue; Humans; Modafinil; Neoplasms; Randomized Controlled Trials a | 2009 |
Pharmacological treatments for fatigue associated with palliative care.
Topics: Adult; Amantadine; Benzhydryl Compounds; Central Nervous System Stimulants; Fatigue; Humans; Kidney | 2010 |
The use of psychostimulants in cancer patients.
Topics: Adult; Antineoplastic Agents; Asthenia; Benzhydryl Compounds; Central Nervous System Stimulants; Chi | 2011 |
Management of cancer-related fatigue.
Topics: Antidepressive Agents; Benzhydryl Compounds; Depression; Fatigue; Glucocorticoids; Humans; Modafinil | 2005 |
10 trials available for modafinil and Neoplasms
| Article | Year |
|---|---|
Efficacy and safety of modafinil versus dexamethasone in cancer-related fatigue: a prospective randomized controlled study.
Topics: Administration, Oral; Adult; Aged; Dexamethasone; Double-Blind Method; Fatigue; Female; Follow-Up St | 2021 |
Randomized placebo-controlled trial of cognitive behavioral therapy and armodafinil for insomnia after cancer treatment.
Topics: Benzhydryl Compounds; Breast Neoplasms; Cognitive Behavioral Therapy; Combined Modality Therapy; Fem | 2015 |
Cognitive behavioral therapy for insomnia, but not armodafinil, improves fatigue in cancer survivors with insomnia: a randomized placebo-controlled trial.
Topics: Benzhydryl Compounds; Cognitive Behavioral Therapy; Combined Modality Therapy; Fatigue; Female; Foll | 2016 |
Modafinil Moderates the Relationship Between Cancer-Related Fatigue and Depression in 541 Patients Receiving Chemotherapy.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Benzhydryl Compounds; Depression; Double-Blind Method; F | 2016 |
Effects of armodafinil and cognitive behavior therapy for insomnia on sleep continuity and daytime sleepiness in cancer survivors.
Topics: Benzhydryl Compounds; Cognitive Behavioral Therapy; Disorders of Excessive Somnolence; Female; Human | 2016 |
Effects of cognitive behavioral therapy for insomnia and armodafinil on quality of life in cancer survivors: a randomized placebo-controlled trial.
Topics: Adult; Aged; Benzhydryl Compounds; Cognitive Behavioral Therapy; Female; Humans; Male; Middle Aged; | 2017 |
A pilot study evaluating the safety and efficacy of modafinal for cancer-related fatigue.
Topics: Activities of Daily Living; Affect; Benzhydryl Compounds; Central Nervous System Stimulants; Drug-Re | 2009 |
Modafinil for attentional and psychomotor dysfunction in advanced cancer: a double-blind, randomised, cross-over trial.
Topics: Adult; Aged; Attention; Benzhydryl Compounds; Central Nervous System Stimulants; Cognition Disorders | 2009 |
A phase 3 randomized, placebo-controlled, double-blind, clinical trial of the effect of modafinil on cancer-related fatigue among 631 patients receiving chemotherapy: a University of Rochester Cancer Center Community Clinical Oncology Program Research bas
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Benzhydryl Compounds; Central Ner | 2010 |
A phase 3 randomized, placebo-controlled, double-blind, clinical trial of the effect of modafinil on cancer-related fatigue among 631 patients receiving chemotherapy: a University of Rochester Cancer Center Community Clinical Oncology Program Research bas
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Benzhydryl Compounds; Central Ner | 2010 |
A phase 3 randomized, placebo-controlled, double-blind, clinical trial of the effect of modafinil on cancer-related fatigue among 631 patients receiving chemotherapy: a University of Rochester Cancer Center Community Clinical Oncology Program Research bas
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Benzhydryl Compounds; Central Ner | 2010 |
A phase 3 randomized, placebo-controlled, double-blind, clinical trial of the effect of modafinil on cancer-related fatigue among 631 patients receiving chemotherapy: a University of Rochester Cancer Center Community Clinical Oncology Program Research bas
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Benzhydryl Compounds; Central Ner | 2010 |
Phase 1 study of MLN8054, a selective inhibitor of Aurora A kinase in patients with advanced solid tumors.
Topics: Administration, Oral; Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Aurora Kinases; Benzaze | 2011 |
5 other studies available for modafinil and Neoplasms
| Article | Year |
|---|---|
Recommendations for high-priority research on cancer-related fatigue in children and adults.
Topics: Adult; Anxiety; Benzhydryl Compounds; Bupropion; Central Nervous System Stimulants; Child; Clinical | 2013 |
Recommendations for high-priority research on cancer-related fatigue in children and adults.
Topics: Adult; Anxiety; Benzhydryl Compounds; Bupropion; Central Nervous System Stimulants; Child; Clinical | 2013 |
Recommendations for high-priority research on cancer-related fatigue in children and adults.
Topics: Adult; Anxiety; Benzhydryl Compounds; Bupropion; Central Nervous System Stimulants; Child; Clinical | 2013 |
Recommendations for high-priority research on cancer-related fatigue in children and adults.
Topics: Adult; Anxiety; Benzhydryl Compounds; Bupropion; Central Nervous System Stimulants; Child; Clinical | 2013 |
Cancer investigators make strides in improving patients' quality of life.
Topics: Acupuncture Therapy; Benzhydryl Compounds; Central Nervous System Stimulants; Fatigue; Humans; Modaf | 2008 |
No rest for fatigue researchers.
Topics: Activities of Daily Living; Anemia; Antineoplastic Agents; Benzhydryl Compounds; Central Nervous Sys | 2008 |
[Modafinil for the treatment of cancer-related fatigue : an intervention study].
Topics: Activities of Daily Living; Adult; Aged; Aged, 80 and over; Benzhydryl Compounds; Central Nervous Sy | 2010 |
Medicinal studies in palliative care: impact of the EU clinical trials directive.
Topics: Benzhydryl Compounds; Biomedical Research; Central Nervous System Stimulants; Clinical Trials as Top | 2007 |